- Home
- RARE vs NMRK Comparison
RARE vs NMRK Comparison
Compare RARE & NMRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RARE
- NMRK
- Stock Information
- Founded
- RARE 2010
- NMRK 1929
- Country
- RARE United States
- NMRK United States
- Employees
- RARE N/A
- NMRK N/A
- Industry
- RARE Biotechnology: Pharmaceutical Preparations
- NMRK Real Estate
- Sector
- RARE Health Care
- NMRK Finance
- Exchange
- RARE Nasdaq
- NMRK Nasdaq
- Market Cap
- RARE 3.1B
- NMRK 3.4B
- IPO Year
- RARE 2014
- NMRK 2017
- Fundamental
- Price
- RARE $33.28
- NMRK $19.17
- Analyst Decision
- RARE Strong Buy
- NMRK Strong Buy
- Analyst Count
- RARE 13
- NMRK 5
- Target Price
- RARE $87.69
- NMRK $19.00
- AVG Volume (30 Days)
- RARE 1.5M
- NMRK 1.1M
- Earning Date
- RARE 11-03-2025
- NMRK 10-30-2025
- Dividend Yield
- RARE N/A
- NMRK 0.62%
- EPS Growth
- RARE N/A
- NMRK 44.43
- EPS
- RARE N/A
- NMRK 0.36
- Revenue
- RARE $610,159,000.00
- NMRK $2,983,234,000.00
- Revenue This Year
- RARE $19.72
- NMRK $17.66
- Revenue Next Year
- RARE $23.29
- NMRK $9.19
- P/E Ratio
- RARE N/A
- NMRK $53.52
- Revenue Growth
- RARE 26.77
- NMRK 17.28
- 52 Week Low
- RARE $25.81
- NMRK $9.65
- 52 Week High
- RARE $56.38
- NMRK $19.78
- Technical
- Relative Strength Index (RSI)
- RARE 58.42
- NMRK 63.47
- Support Level
- RARE $32.40
- NMRK $17.70
- Resistance Level
- RARE $34.78
- NMRK $18.55
- Average True Range (ATR)
- RARE 1.26
- NMRK 0.56
- MACD
- RARE 0.27
- NMRK 0.10
- Stochastic Oscillator
- RARE 71.21
- NMRK 99.56
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
About NMRK Newmark Group Inc.
Newmark Group Inc is a commercial real estate advisory firm. It offers services, including leasing and corporate advisory services, investment sales, commercial mortgage brokerage, appraisal and valuation, project management, and property, among others. Newmark offers a diverse array of integrated services and products designed to meet the full needs of both real estate investors/owners and occupiers. The company provides real estate strategic consulting and systems integration services to CFI's clients including many Fortune and Forbes companies, owner-occupiers, government agencies, healthcare, and higher education clients.